2026³â08¿ù02ÀÏsun
·Î±×ÀÎ | ȸ¿ø°¡ÀÔ
OFF
Æ®À§ÅÍ·Î º¸³»±â ½ÎÀÌ¿ùµå °ø°¨
±â»ç±ÛÈ®´ë ±â»ç±ÛÃà¼Ò ±â»ç½ºÅ©·¦ À̸ÞÀϹ®ÀÇ ÇÁ¸°Æ®Çϱâ
À¯ÇÑÀÇÇлó ´ë»ó, ¾Æ»ê ¹Ú´ö¿ì¡¤»ï¼º °í¿øÁß ±³¼ö
[ 2009³â 04¿ù 16ÀÏ 14½Ã 41ºÐ ]
¼­¿ï¾Æ»êº´¿ø ¹Ú´ö¿ì ±³¼ö¿Í »ï¼º¼­¿ïº´¿ø °í¿øÁß ±³¼ö°¡ À¯ÇÑÀÇÇлó ´ë»óÀ» ¼ö»óÇß´Ù.

¼­¿ï½ÃÀÇ»çȸ´Â Áö³­ 15ÀÏ È¸°ü 5Ãþ µ¿¾ÆÈ¦¿¡¼­ ÀÇ»ç½Å¹®(»çÀå ³ªÇö ¼­¿ïƯº°½ÃÀÇ»çȸÀå) â°£ 49Áֳ⠱â³ä½Ä ¹× Á¦42ȸ À¯ÇÑÀÇÇлó ½Ã»ó½ÄÀ» °³ÃֵƴÙ.

À̳¯ ½Ã»ó½Ä¿¡¼­ ¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø ½ÉÀå³»°ú ¹Ú´ö¿ì ±³¼ö´Â ¡®Long-Term Mortality After Percutaneous Coronary Intervention With Drug-Eluting Stent Implantation Versus Coronary Artery Bypass Surgery for the Treatment of Multivessel Coronary Artery Disease¡¯¸¦ ÁÖÁ¦·Î ´ë»óÀ» ¼ö»óÇß´Ù.

¶Ç ¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø È£Èí±â³»°ú °í¿øÁß ±³¼öµµ ¡®Treatment Outcomes for HIV-Uninfected Patients with Multidrug-Resistant and Extensively Drug-Resistant Tuberculosi¡¯¸¦ ÁÖÁ¦·Î ÇÑ ³í¹®À¸·Î ´ë»óÀ» ¹Þ¾Ò´Ù.

À¯ÇÑÀÇÇлóÀº 2009³âµµ(Á¦42ȸ)ºÎÅÍ Á¾ÀüÀÇ ´ë»ó, ¿ì¼ö»ó, Àå·Á»ó °¢ 1¸í¿¡¼­ ´ë»ó 2¸íÀ» ¼±Á¤ÇØ ¼øÀ§¸¦ ±¸ºÐÇÏÁö ¾Ê°í »ó±ÝÀ» µ¿ÀÏÇÏ°Ô Áö±ÞÇÔÀ¸·Î½á À§»óÀ» °Ý»ó½ÃÄ×´Ù. ¼ö»óÀÚ¿¡°Ô´Â °¢ 2000¸¸¿øÀÇ »ó±ÝÀÌ ¼ö¿©µÆ´Ù.
±èµµ°æ±âÀÚ kimdo@dailymedi.com
À̱âÀÚÀÇ ´Ù¸¥´º½ºº¸±â
¹«ÅëÀåÀÔ±Ý Á¤º¸ÀÔ·Â ÀÔ±ÝÀÚ¸í ÀԱݿ¹Á¤ÀÏÀÚ
(ÀÔ±ÝÇÏ½Ç ÀÔ±ÝÀÚ¸í + ÀԱݿ¹Á¤ÀÏÀÚ¸¦ ÀÔ·ÂÇϼ¼¿ä)
[°ü·Ã´º½º]
- °ü·Ã´º½º°¡ ¾ø½À´Ï´Ù.
Æ®À§ÅÍ·Î º¸³»±â ½ÎÀÌ¿ùµå °ø°¨
±â»ç±ÛÈ®´ë ±â»ç±ÛÃà¼Ò ±â»ç½ºÅ©·¦ À̸ÞÀϹ®ÀÇ ÇÁ¸°Æ®Çϱâ
¸íÁöº´¿ø, ͺ À̰ÇÈñ ȸÀå ÁÖÄ¡ÀÇ À̰­¿ì ±³¼ö(»ï¼º¼­¿ïº´¿ø ÀçȰÀÇÇаú) ¿µÀÔ
´ëÀü¼º¸ðº´¿ø ±èµ¿±â¡¤À̵¿Ã¢ ±³¼ö, ´ëÇÑÀ̺ñÀÎÈİúÇÐȸ ÃÖ¿ì¼ö ±¸¿¬»ó¡¤ÃÖ¿ì¼ö Æ÷½ºÅÍ»ó
Á¶Àç¿ì ±³¼ö(°í´ë±¸·Îº´¿ø Á¤Çü¿Ü°ú), ´ëÇѰñÀýÇÐȸ ÃÖ´Ù³í¹®»ó
´ëÇÑÀÇ»çÇùȸ ºÎȸÀå ¹éÇö¿í¡¤Àǹ«ÀÌ»ç ¿Àµ¿È£¡¤Á¤º¸Åë½ÅÀÌ»ç À¯¼Ò¿µèâ
Çѱ¹Á¦¾à¹ÙÀÌ¿ÀÇùȸ ÀǾàǰ±¤°í½ÉÀÇÀ§¿øÈ¸ À§¿øÀå ±è¼ºÁø¡¤ºÎÀ§¿øÀå ÀÌÁØÈñ¡¤ÀåÃá°ï èâ
¹è±â¼ö ±³¼ö(¾ÆÁִ뺴¿ø ¼Ò¾ÆÃ»¼Ò³â°ú), Á¦100ȸ ¾î¸°À̳¯ ¿ÁÁ¶±ÙÁ¤ÈÆÀå
À̺´ÈÆ¡¤½ÉÀç¾Ó ±³¼öÆÀ(±æº´¿ø Á¤Çü¿Ü°ú), ´ëÇѰñÀýÇÐȸ ¿ÃÇØ ¿ì¼ö ±¸¿¬»ó
³²°¡Àº ±³¼ö(°í´ë±¸·Îº´¿ø °¡Á¤ÀÇÇаú), Çѱ¹¿©ÀÚÀÇ»çȸ Á¦4ȸ ÀþÀºÀÇÇÐÀÚ Çмú»ó
±¹¸³Áß¾ÓÀÇ·á¿ø Áß¾ÓÀÀ±ÞÀÇ·á¼¾ÅÍÀå ±è¼ºÁß(Á¶¼±´ëº´¿ø ÀÀ±ÞÀÇÇаú ±³¼ö)
ÃÖÁ¤¿õ ¿µ°æÀÇ·áÀç´Ü ÀüÁÖº´¿ø ÀÌ»çÀå, ¾Æµ¿º¸È£»ç¾÷ ±â±Ý 4000¸¸¿ø
±è¿µÁÖ ±³¼ö(ÀÌ´ë¸ñµ¿º´¿ø »êºÎÀΰú), Á¦13ȸ Çѵ¶¿©ÀÇ»çÇмú´ë»ó
¹ÚÂùÈì ±³¼ö(ÇѸ²´ëÃáõ¼º½Éº´¿ø À̺ñÀÎÈİú), ´ëÇÑÀ̺ñÀÎÈİúÇÐȸ Çмú»ó
Á¶¼öÁø ±³¼ö(ÇѸ²´ëµ¿Åº¼º½Éº´¿ø ½Å°æ°ú), Á¦26ȸ JWÁß¿ÜÇмú´ë»ó
¼­Á¤°Ç ¿¬¼¼¼­³»°ú ¿øÀå ÀåÀλó